Iraq vs South-East Asia (WHO region): HIV-positive TB patients on ART (antiretroviral therapy)
Iraq
100.0%
in 2021
South-East Asia (WHO region)
94.0%
in 2024
Iraq rank
1st
South-East Asia (WHO region) rank
4th
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Iraq
- South-East Asia (WHO region)
How they compare
Iraq currently reports 100.0% against 94.0% in South-East Asia (WHO region), a difference of 6.0%.
That makes Iraq's figure about 1.1 times South-East Asia (WHO region)'s.
The two have swapped places 1 time across 5 shared years of data; in 2011 it was South-East Asia (WHO region) ahead.
Iraq ranks 1st and South-East Asia (WHO region) ranks 4th of 144 countries.
Across the 2 decades both report, Iraq averaged higher in 1 and South-East Asia (WHO region) in 1.
Head to head by decade
| Decade | Iraq | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 66.7% | 69.7% | 3.0% | South-East Asia (WHO region) |
| 2020s | 100.0% | 89.0% | 11.0% | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Iraq or South-East Asia (WHO region)?
- Iraq, at 100.0% against 94.0% in South-East Asia (WHO region) as of 2021.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Iraq and South-East Asia (WHO region)?
- 6.0%, with Iraq ahead.
- How many years of comparable data are there for Iraq and South-East Asia (WHO region)?
- 5 years are reported by both, from 2011 to 2021.
- How do Iraq and South-East Asia (WHO region) rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Iraq ranks 1st and South-East Asia (WHO region) ranks 4th of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.